The global anti-rheumatics market accounted for $57,229 million in 2018 and is expected to reach $71,934 million by 2026, registering a CAGR of 2.9% from 2019 to 2026. Rheumatoid arthritis (RA) is a chronic auto-immune disorder that majorly affects joints along with articular tissues and extra-articular organs. Furthermore, this medical condition is often progressive and results in pain, stiffness, and swelling of joints. Moreover, there is no permanent cure for RA, the goals of the treatment are to reduce pain, decrease inflammation, prevent bone deformity, and improve a person’s overall function. This is achieved through pain medication, steroids, and NSAIDs that are frequently used to help with the symptoms. In addition, disease-modifying anti-rheumatic drugs (DMARDs) are used to slow down the progression of this disease. These drugs are the primary treatment for RA and have been found to improve symptoms, decrease joint damage, and improve overall functional abilities. However, early diagnosis and early treatment is the key for better management of the disease. Recent advancements with biosimilars, which may be used to treat RA and an increase in approvals of the same by regulatory authorities have opened new avenues for the anti-rheumatics market.
The major factors that fuel the growth of the global rheumatoid arthritis drugs market include rise in incidence of rheumatoid arthritis and surge in geriatric population across the globe. In addition, increase in incidence of obesity worldwide is another major factor that drives the growth of anti-rheumatic market. However, side effects associated with the medication and higher cost of biologics & biosimilars restrain the growth of rheumatoid arthritis drug market. On the contrary, developments in the field of biosimilars and novel biologics are anticipated to offer profitable opportunities for the growth of the RA drugs market.
The anti-rheumatics market size is studied on the basis of drug class, type, and region to provide a detailed assessment of the market. On the basis of drug class, it is divided into disease modifying anti-rheumatic drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. By type, it is divided into prescription-based drugs and over-the-counter drugs. By region, the anti-rheumatics market size is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
Key Market Segments
By Drug Class
By Type
By Region
List of key players profiled in the report:
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
The anti-rheumatics market size is studied on the basis of drug class, type, and region to provide a detailed assessment of the market. On the basis of drug class, it is divided into disease modifying anti-rheumatic drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. By type, it is divided into prescription-based drugs and over-the-counter drugs. By region, the anti-rheumatics market size is analyzed across North America (the U.S., Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current global anti-rheumatics market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The market size and estimations are based on a comprehensive analysis of key developments in the industry.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Drug Class
- Disease Modifying Anti-rheumatic Drugs (DMARD's)
- Nonsteroidal Anti-inflammatory Drugs (NSAID's)
- Corticosteroids
- Uric Acid Drugs
- Others
By Type
- Prescription-Based Drugs
- Over-the-Counter Drugs
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
List of key players profiled in the report:
- Pfizer, Inc.
- Johnson & Johnsons
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Celegene Corporations
- MedImmune, LLC
- Takeda Pharmaceutical Company Ltd.
- Biogen Inc.
- Celltrion Inc.
- Amgen Inc
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Sebela Pharmaceuticals
- Abbott LaboratoriesSafe In Breastfeeding
Table of Contents
Chapter 1: Introduction
Chapter 2: Executive Summary
Chapter 3: Market Overview
Chapter 4: Anti-Rheumatics Market, By Drug Class
Chapter 5: Anti-Rheumatics Market, By Type
Chapter 6: Anti-Rheumatics Market, By Region
Chapter 7: Company Profiles
Executive Summary
According to the report, titled, 'Anti-Rheumatics Market by Drug Class and Type: Global Opportunity Analysis and Industry Forecast, 2018-2026,' the global anti-rheumatics market was valued at $57 billion in 2018, and is expected to reach $71 billion by 2026, registering a CAGR of 2.9% from 2019 to 2026.Rheumatoid arthritis is an autoimmune disorder, which causes painful and swollen joints in patients. The treatment of this medical condition involves the use of various drugs, known as anti-rheumatics. For instance, different type of drugs involved in the treatment of rheumatoid arthritis include disease modifying anti-rheumatic drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, and others. These drugs have different mechanism of action on the medical condition. For instance, DMARDs modify the course of the action and NSAIDs act on the symptoms of the disease such as pain. Furthermore, these drugs are available on prescription and also over-the-counter.
The major factor that boosts the growth of the anti-rheumatics market include surge in geriatric population worldwide. Furthermore, surge in the incidences of rheumatoid arthritis is another major factor that contributes toward the growth of the market. In addition, the increase in incidences of obesity across the globe propels the growth of the anti-rheumatics market. Furthermore, the growth potential offered by rise in awareness related to early screening and treatment of rheumatoid arthritis during the forecast period offers lucrative opportunities for the growth of the market. However, the high price of biologics hinder the growth of the market
The anti-rheumatics market size is studied on the basis of drug class, type, and region to provide a detailed assessment of the market. By drug class, it is divided into disease modifying anti-rheumatic drugs (DMARD's), nonsteroidal anti-inflammatory drugs (NSAID's), corticosteroids, uric acid drugs, and others. By on type, the market is bifurcated into prescription-based drugs and over-the-counter drugs. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
According to drug class, the disease modifying anti-rheumatic drugs occupied the largest anti-rheumatics market share in 2018, owing to their action on the medical condition. For instance, DMARDs act on the underlying medical condition rather than acting on the symptoms. Furthermore, the nonsteroidal anti-inflammatory drugs segment is expected to register the fastest growth during the forecast period, owing to the surge in incidences of rheumatoid arthritis associated with pain in the joints.
By type, the prescription-based drugs segment occupied the largest share, owing to rise in the number of specialized hospitals worldwide as the medical condition requires treatment from a specialized medical professional. Furthermore, the over-the-counter drugs segment is expected to exhibit the fastest growth rate during the forecast period, owing to surge in awareness related to treatment options available for rheumatoid arthritis. Moreover, easy availability of NSAIDs over-the-counter is another major factor that contributes to the growth of the anti-rheumatics market.
In 2018, North America accounted for the major share of anti-rheumatics market size and is expected to remain dominant, owing to easy availability of the anti-rheumatics in this region. Moreover, surge in geriatric population in the region is another major factor that fuels the growth of anti-rheumatic market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period, owing to surge in awareness related to the use of anti-rheumatics.
The developing economies offer lucrative opportunities for anti-rheumatics providers to expand their business. The constantly evolving life science industry drives the growth of the market in the developing economies such as India, and China.
Key Findings of the Study
The disease modifying anti-rheumatic drugs segment occupied approximately two-fifth share of the global anti-rheumatics market in 2018.
The nonsteroidal anti-inflammatory drugs segment is anticipated to grow at the highest CAGR throughout the forecast period.
The prescription-based drugs segment accounted for three-fourth share of the market in 2018.
Asia-Pacific is anticipated to grow at the fastest rate during the analysis period, followed by LAMEA.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnsons
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- Celegene Corporations
- MedImmune LLC
- Takeda Pharmaceutical Company Ltd.
- Biogen Inc.
- Celltrion Inc.
- Amgen Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
